Angiex Inc

Angiex Inc. is a privately held biotechnology startup based in Cambridge, Massachusetts. The company employs 9 people and generates an annual revenue of $6 million. Angiex is focused on developing a novel portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs). These innovative drugs are designed to release therapeutic payloads directly into the nucleus or cytosol of cancer cells, maximizing their effectiveness. The company's mission is to leverage newly discovered biological transport mechanisms to create groundbreaking cancer treatments. Angiex was founded by a team of leading experts in angiogenesis, vascular biology, and oncology, bringing a wealth of experience and knowledge to the development of its groundbreaking therapies. For more information about Angiex Inc. and its innovative cancer treatments, please visit angiex.com.